Cargando…

Timing of antibiotic therapy in the ICU

Severe or life threatening infections are common among patients in the intensive care unit (ICU). Most infections in the ICU are bacterial or fungal in origin and require antimicrobial therapy for clinical resolution. Antibiotics are the cornerstone of therapy for infected critically ill patients. H...

Descripción completa

Detalles Bibliográficos
Autores principales: Kollef, Marin H., Shorr, Andrew F., Bassetti, Matteo, Timsit, Jean-Francois, Micek, Scott T., Michelson, Andrew P., Garnacho-Montero, Jose
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8518273/
https://www.ncbi.nlm.nih.gov/pubmed/34654462
http://dx.doi.org/10.1186/s13054-021-03787-z
_version_ 1784584188015411200
author Kollef, Marin H.
Shorr, Andrew F.
Bassetti, Matteo
Timsit, Jean-Francois
Micek, Scott T.
Michelson, Andrew P.
Garnacho-Montero, Jose
author_facet Kollef, Marin H.
Shorr, Andrew F.
Bassetti, Matteo
Timsit, Jean-Francois
Micek, Scott T.
Michelson, Andrew P.
Garnacho-Montero, Jose
author_sort Kollef, Marin H.
collection PubMed
description Severe or life threatening infections are common among patients in the intensive care unit (ICU). Most infections in the ICU are bacterial or fungal in origin and require antimicrobial therapy for clinical resolution. Antibiotics are the cornerstone of therapy for infected critically ill patients. However, antibiotics are often not optimally administered resulting in less favorable patient outcomes including greater mortality. The timing of antibiotics in patients with life threatening infections including sepsis and septic shock is now recognized as one of the most important determinants of survival for this population. Individuals who have a delay in the administration of antibiotic therapy for serious infections can have a doubling or more in their mortality. Additionally, the timing of an appropriate antibiotic regimen, one that is active against the offending pathogens based on in vitro susceptibility, also influences survival. Thus not only is early empiric antibiotic administration important but the selection of those agents is crucial as well. The duration of antibiotic infusions, especially for β-lactams, can also influence antibiotic efficacy by increasing antimicrobial drug exposure for the offending pathogen. However, due to mounting antibiotic resistance, aggressive antimicrobial de-escalation based on microbiology results is necessary to counterbalance the pressures of early broad-spectrum antibiotic therapy. In this review, we examine time related variables impacting antibiotic optimization as it relates to the treatment of life threatening infections in the ICU. In addition to highlighting the importance of antibiotic timing in the ICU we hope to provide an approach to antimicrobials that also minimizes the unnecessary use of these agents. Such approaches will increasingly be linked to advances in molecular microbiology testing and artificial intelligence/machine learning. Such advances should help identify patients needing empiric antibiotic therapy at an earlier time point as well as the specific antibiotics required in order to avoid unnecessary administration of broad-spectrum antibiotics.
format Online
Article
Text
id pubmed-8518273
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-85182732021-10-15 Timing of antibiotic therapy in the ICU Kollef, Marin H. Shorr, Andrew F. Bassetti, Matteo Timsit, Jean-Francois Micek, Scott T. Michelson, Andrew P. Garnacho-Montero, Jose Crit Care Review Severe or life threatening infections are common among patients in the intensive care unit (ICU). Most infections in the ICU are bacterial or fungal in origin and require antimicrobial therapy for clinical resolution. Antibiotics are the cornerstone of therapy for infected critically ill patients. However, antibiotics are often not optimally administered resulting in less favorable patient outcomes including greater mortality. The timing of antibiotics in patients with life threatening infections including sepsis and septic shock is now recognized as one of the most important determinants of survival for this population. Individuals who have a delay in the administration of antibiotic therapy for serious infections can have a doubling or more in their mortality. Additionally, the timing of an appropriate antibiotic regimen, one that is active against the offending pathogens based on in vitro susceptibility, also influences survival. Thus not only is early empiric antibiotic administration important but the selection of those agents is crucial as well. The duration of antibiotic infusions, especially for β-lactams, can also influence antibiotic efficacy by increasing antimicrobial drug exposure for the offending pathogen. However, due to mounting antibiotic resistance, aggressive antimicrobial de-escalation based on microbiology results is necessary to counterbalance the pressures of early broad-spectrum antibiotic therapy. In this review, we examine time related variables impacting antibiotic optimization as it relates to the treatment of life threatening infections in the ICU. In addition to highlighting the importance of antibiotic timing in the ICU we hope to provide an approach to antimicrobials that also minimizes the unnecessary use of these agents. Such approaches will increasingly be linked to advances in molecular microbiology testing and artificial intelligence/machine learning. Such advances should help identify patients needing empiric antibiotic therapy at an earlier time point as well as the specific antibiotics required in order to avoid unnecessary administration of broad-spectrum antibiotics. BioMed Central 2021-10-15 /pmc/articles/PMC8518273/ /pubmed/34654462 http://dx.doi.org/10.1186/s13054-021-03787-z Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Kollef, Marin H.
Shorr, Andrew F.
Bassetti, Matteo
Timsit, Jean-Francois
Micek, Scott T.
Michelson, Andrew P.
Garnacho-Montero, Jose
Timing of antibiotic therapy in the ICU
title Timing of antibiotic therapy in the ICU
title_full Timing of antibiotic therapy in the ICU
title_fullStr Timing of antibiotic therapy in the ICU
title_full_unstemmed Timing of antibiotic therapy in the ICU
title_short Timing of antibiotic therapy in the ICU
title_sort timing of antibiotic therapy in the icu
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8518273/
https://www.ncbi.nlm.nih.gov/pubmed/34654462
http://dx.doi.org/10.1186/s13054-021-03787-z
work_keys_str_mv AT kollefmarinh timingofantibiotictherapyintheicu
AT shorrandrewf timingofantibiotictherapyintheicu
AT bassettimatteo timingofantibiotictherapyintheicu
AT timsitjeanfrancois timingofantibiotictherapyintheicu
AT micekscottt timingofantibiotictherapyintheicu
AT michelsonandrewp timingofantibiotictherapyintheicu
AT garnachomonterojose timingofantibiotictherapyintheicu